The Uppsala-based company Gradientech has developed a method for ultra-rapid antibiotic susceptibility testing, which aims to ensure that sepsis patients, in particular, can receive the optimal antibiotic treatment.
CEO Sara Thorslund co-founded the company in 2009, and at that time the basic method that has been developed over time and is now use...
Developing rapid diagnostics for sepsis – “Every hour counts”
Finding the right antibiotic in the right dose – with an ultra-fast analysis method. Gradientech's product solution is currently used in routine diagnostics at several hospitals in Europe – and the next target is the US market.
Sara Thorslund, CEO Gradientech. Photo: Gradientech
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration